Stocks On the Move: Momenta Pharmaceuticals, Inc., Pacira Pharmaceuticals Inc, and Stemline Therapeutics Inc

MNTA, PCRX, and STML are among the stocks on the move today

Jan 6, 2017 at 1:15 PM
facebook X logo linkedin

U.S. stocks have recovered after a rocky start to the day, with multiple indexes touching record highs. Among specific equities in focus today are drug stocks Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), Pacira Pharmaceuticals Inc (NASDAQ:PCRX), and Stemline Therapeutics Inc (NASDAQ:STML). Here's a quick look at what's moving MNTA, PCRX, and STML.

  • MNTA is up 6.1% at $16.45, and fresh off an annual high of $17.25, after the drugmaker announced a license agreement with CSL. Separately, Momenta Pharmaceuticals, Inc. reiterated its fourth-quarter adjusted operating expense guidance as part of its 2016 corporate update. The brokerage community isn't being caught off guard by the stock's sharp gains. Two-thirds of the nine covering analysts rate MNTA a "strong buy."
  • PCRX has gapped 17.2% higher to trade at $40.03, boosted by better-than-expected preliminary fourth-quarter revenue numbers. Bolstering sales was demand for the company's non-opioid anesthetic Exparel, and Pacira Pharmaceuticals Inc said it's seeing "strong interest" from potential partners that want to broaden applications for the drug. Longer term, however, the shares have fallen a long way since this time last year, when they were flirting with the $70 level. Meanwhile, short sellers are likely getting burned on PCRX's breakout. After jumping about 27% in the most recent reporting period, short interest now accounts for roughly 13% of the stock's float -- more than a week's worth of trading activity, based on average daily levels.
  • STML is over 14% higher at $12.95, after the firm reached an agreement with the Food and Drug Administration (FDA) on a pathway for full approval of its leukemia treatment, SL-401. Year-over-year, the shares have now advanced over 124%. Yet, short-term open interest levels on Stemline Therapeutics Inc are very put-skewed, relatively speaking. The stock's Schaeffer's put/call open interest ratio (SOIR) of 0.73 ranks just 12 percentage points from an annual high.
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI